Research News

Exploring the clinical usefulness of the low-FODMAP diet for Crohn’s disease

Tuesday, 18 October 2016 11:26

A diet low in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) has been studied mostly in the context of irritable bowel syndrome (IBS) and is known to reduce functional gastrointestinal symptoms in this population. In addition, altering FODMAP intake appears to impact fecal microbiota composition in both healthy individuals and those with IBS.

The observed success of the low-FODMAP diet in reducing gastrointestinal (GI) symptoms in IBS made a group of researchers ask whether the diet could also address functional GI symptoms in those with inflammatory bowel diseases (IBDs) such as Crohn’s disease. This idea was explored in a recent study from the group at Monash University (Australia) that originally developed and tested the low-FODMAP diet.

In this cross-over trial, researchers first tracked the habitual diets of a small group of nine patients with inactive Crohn’s disease. Next, each participant was randomized to 21 days of a provided experimental diet: either (1) low-FODMAP or (2) typical “Australian”. After a washout period of his or her habitual diet for at least 21 days (until GI symptoms had returned to baseline), each participant consumed the other experimental diet for an additional 21 days.

Further Information

Dietary fibre/short-chain fatty acids and vitamin A may protect mice against peanut allergy via gut microbiota

Tuesday, 18 October 2016 11:18

The incidence of food allergies has increased dramatically in western countries over the past 20 years and the gut microbiota seems to be a promising target for preventing and treating them. However, mechanisms by which gut microbiota is involved in the loss of oral tolerance remain unclear.

A recent study, led by Dr. Charles Mackay from the Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology at Monash University in Clayton (Australia), has found that the development of food allergies in mice could be linked to dietary elements including fibre and vitamin A.

Further Information

Probiotics could help combat small intestinal bacterial overgrowth in patients with gastrointestinal cancer

Tuesday, 18 October 2016 11:10

Small intestinal bacterial overgrowth (SIBO) refers to a condition in which abnormally large numbers of bacteria are present in the small intestine. Gastrointestinal cancer is related to compromised intestinal barrier function, reduced functionality of immune responses, and inadequate nutritional status, which impair the ability of patients to control intestinal bacterial proliferation. These result in conditions favourable to SIBO. However, the actual incidence of SIBO in patients with gastrointestinal cancer and its relation to clinical symptoms has not been explored.

A recent case-control study, led by Dr. Zhenjun Wu from the Department of Blood Transfusion and Clinical Laboratory at Qingdao University School of Medicine in Qingdao (China), has found that probiotics may combat SIBO in patients with gastrointestinal cancer and may alleviate some gastrointestinal symptoms.

Further Information

Gut bacteria alterations impact serum metabolites and may contribute to insulin resistance

Tuesday, 18 October 2016 10:41

A mounting body of scientific evidence suggests a link between the gut microbiome and human metabolic health. Indeed, alteration of microbial composition and function in patients with type 2 diabetes (T2D) appears to be a key feature in the pathogenesis of the disease. However, whether the insulin resistance (IR)-associated serum metabolome may predict metabolic and cardiovascular disorders is unknown.

A recent study, led by Dr. Oluf Pedersen from the Faculty of Health and Medical Sciences at University of Copenhagen in Denmark, has found that dysbiosis of the human gut microbiota impacts the serum metabolome and contributes to the state of IR and metabolic syndrome.

The researchers examined 277 non-diabetic Danish adults and 75 Danish T2D patients with preserved insulin secretion. Analyses included the serum for metabolomics (it provided information about more than 1200 metabolites) and the stool for metagenomics.

Further Information

Page 10 of 36